Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000635039 | SCV000756417 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2023-08-27 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764010 | SCV000894962 | uncertain significance | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2022-02-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003162835 | SCV003877890 | uncertain significance | Inborn genetic diseases | 2023-03-07 | criteria provided, single submitter | clinical testing | The c.171G>T (p.E57D) alteration is located in exon 2 (coding exon 1) of the CACNA1H gene. This alteration results from a G to T substitution at nucleotide position 171, causing the glutamic acid (E) at amino acid position 57 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004691977 | SCV005194068 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Gene |
RCV004691977 | SCV005628476 | uncertain significance | not provided | 2024-07-17 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |